Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 268390, 12 pages
http://dx.doi.org/10.1155/2015/268390
Review Article

Diabetic Foot Syndrome as a Possible Cardiovascular Marker in Diabetic Patients

Dipartimento Biomedico di Medicina Interna e Specialistica, U.O.C di Medicina Interna e Cardioangiologia, Università degli Studi di Palermo, Piazza delle Cliniche, No. 2, 90127 Palermo, Italy

Received 10 December 2014; Accepted 18 March 2015

Academic Editor: Shi Fang Yan

Copyright © 2015 Antonino Tuttolomondo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Working Group on the Diabetic Foot, Consensus on the Diabetic Foot and Practical Guidelines on the Management and the Prevention of the Diabetic Foot, International Diabetes Federation, Amsterdam, The Netherlands, 2011, http://www.diabeticfoot.nl/.
  2. A. J. Boulton, L. Vileikyte, G. Ragnarson-Tennvall, and J. Apelqvist, “The global burden of diabetic foot disease,” The Lancet, vol. 366, no. 9498, pp. 1719–1724, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. W. J. Jeffcoate, R. M. Macfarlane, and E. M. Fletcher, “The description and classification of diabetic foot lesions,” Diabetic Medicine, vol. 10, no. 7, pp. 676–679, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. Centers for Disease Control and Prevention, National Diabetes Fact Sheet. National Estimates on Diabetes, Centers for Disease Control and Prevention, Atlanta, Ga, USA, 2003.
  5. American Diabetes Association, “Consensus development conference on diabetic foot wound care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association,” Diabetes Care, vol. 22, no. 8, pp. 1354–1360, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. R. E. Pecoraro, G. E. Reiber, and E. M. Burgess, “Pathways to diabetic limb amputation: basis for prevention,” Diabetes Care, vol. 13, no. 5, pp. 513–521, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. M. P. Khanolkar, S. C. Bain, and J. W. Stephens, “The diabetic foot,” QJM, vol. 101, no. 9, pp. 685–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. G. E. Reiber, “Epidemiology of foot ulcers and amputations in the diabetic foot,” in The Diabetic Foot, J. H. Bowker and M. A. Pfeifer, Eds., pp. 13–32, Mosby, St. Louis, Mo, USA, 2001. View at Google Scholar
  9. S. E. Moss, R. Klein, and B. E. K. Klein, “The prevalence and incidence of lower extremity amputation in a diabetic population,” Archives of Internal Medicine, vol. 152, no. 3, pp. 610–616, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. S. D. Ramsey, K. Newton, D. Blough et al., “Incidence, outcomes, and cost of foot ulcers in patients with diabetes,” Diabetes Care, vol. 22, no. 3, pp. 382–387, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. C. A. Abbott, L. Vileikyte, S. Williamson, A. L. Carrington, and A. J. M. Boulton, “Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration,” Diabetes Care, vol. 21, no. 7, pp. 1071–1075, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. D. P. Walters, W. Gatling, M. A. Mullee, and R. D. Hill, “The distribution and severity of diabetic foot disease: a community study with comparison to a non-diabetic group,” Diabetic Medicine, vol. 9, no. 4, pp. 354–358, 1992. View at Publisher · View at Google Scholar · View at Scopus
  13. P. LeQuesne, N. Parkshouse, and I. Faris, “Neuropathy,” in The Management of the Diabetic Foot, I. Faris, Ed., p. 41, Churchill Livingstone, Edinburgh, Scotland, 2nd edition, 1991. View at Google Scholar
  14. G. E. Reiber, D. G. Smith, L. Vileikyte et al., “Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings,” Diabetes Care, vol. 22, no. 1, pp. 157–162, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. R. D. Abbott, F. N. Brand, and W. B. Kannel, “Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study,” The American Journal of Medicine, vol. 88, no. 4, pp. 376–381, 1990. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Daousi, I. A. MacFarlane, A. Woodward, T. J. Nurmikkot, P. E. Bundred, and S. J. Benbow, “Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes,” Diabetic Medicine, vol. 21, no. 9, pp. 976–982, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Pinto, A. Tuttolomondo, D. Di Raimondo et al., “Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot,” Metabolism, vol. 57, no. 5, pp. 676–682, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. N. A. Roper, R. W. Bilous, W. F. Kelly, N. C. Unwin, and V. M. Connolly, “Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study,” British Medical Journal, vol. 322, no. 7299, pp. 1389–1393, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. W. B. Kannel and D. L. McGee, “Diabetes and cardiovascular disease: the Framingham study,” The Journal of the American Medical Association, vol. 241, no. 19, pp. 2035–2038, 1979. View at Publisher · View at Google Scholar · View at Scopus
  20. J. S. Rana, M. Nieuwdorp, J. W. Jukema, and J. J. P. Kastelein, “Cardiovascular metabolic syndrome—an interplay of, obesity, inflammation, diabetes and coronary heart disease,” Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 218–232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Pinto, A. Tuttolomondo, D. di Raimondo et al., “Ischemic stroke in patients with diabetic foot,” International Angiology, vol. 26, no. 3, pp. 266–269, 2007. View at Google Scholar · View at Scopus
  22. A. Tuttolomondo, S. La Placa, D. Di Raimondo et al., “Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity,” Cardiovascular Diabetology, vol. 9, article 50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Sell and J. Eckel, “Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation?” Proceedings of the Nutrition Society, vol. 68, no. 4, pp. 378–384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances in the relationship between obesity, inflammation, and insulin resistance,” European Cytokine Network, vol. 17, no. 1, pp. 4–12, 2006. View at Google Scholar · View at Scopus
  25. L. K. Heilbronn and L. V. Campbell, “Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity,” Current Pharmaceutical Design, vol. 14, no. 12, pp. 1225–1230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Hotta, T. Funahashi, Y. Arita et al., “Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1595–1599, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Kumada, S. Kihara, S. Sumitsuji et al., “Association of hypoadiponectinemia with coronary artery disease in men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 85–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Baratta, S. Amato, C. Degano et al., “Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2665–2671, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Ouchi, S. Kihara, T. Funahashi et al., “Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue,” Circulation, vol. 107, no. 5, pp. 671–674, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. W. J. Jeffcoate, F. Game, and P. R. Cavanagh, “The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes,” The Lancet, vol. 366, no. 9502, pp. 2058–2061, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Meisinger, C. Herder, M. Lankisch et al., “Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany),” Diabetes Care, vol. 32, no. 4, pp. 680–682, 2009. View at Publisher · View at Google Scholar
  32. C. Weigelt, B. Rose, U. Poschen et al., “Immune mediators in patients with acute diabetic foot syndrome,” Diabetes Care, vol. 32, no. 8, pp. 1491–1496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. C. Engert, M.-C. Vohl, S. M. Williams et al., “5′ flanking variants of resistin are associated with obesity,” Diabetes, vol. 51, no. 5, pp. 1629–1634, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. V. S. Mattevi, V. M. Zembrzuski, and M. H. Hutz, “A resistin gene polymorphism is associated with body mass index in women,” Human Genetics, vol. 115, no. 3, pp. 208–212, 2004. View at Google Scholar · View at Scopus
  35. S. Kaser, A. Kaser, A. Sandhofer, C. F. Ebenbichler, H. Tilg, and J. R. Patsch, “Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro,” Biochemical and Biophysical Research Communications, vol. 309, no. 2, pp. 286–290, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Osawa, Y. Doi, H. Makino et al., “Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study,” Cardiovascular Diabetology, vol. 8, article 60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader, “Resistin is an inflammatory marker of atherosclerosis in humans,” Circulation, vol. 111, no. 7, pp. 932–939, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Kawanami, K. Maemura, N. Takeda et al., “Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions,” Biochemical and Biophysical Research Communications, vol. 314, no. 2, pp. 415–419, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Almeda-Valdes, D. Cuevas-Ramos, R. Mehta et al., “Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance,” Cardiovascular Diabetology, vol. 9, article 26, 2010. View at Publisher · View at Google Scholar
  40. N. Ouchi, S. Kihara, Y. Arita et al., “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin,” Circulation, vol. 100, no. 25, pp. 2473–2476, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Yamauchi, J. Kamon, Y. Ito et al., “Cloning of adiponectin receptors that mediate antidiabetic metabolic effects,” Nature, vol. 423, no. 6941, pp. 762–769, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Halvatsiotis, P. C. Tsiotra, I. Ikonomidis et al., “Genetic variation in the adiponectin receptor 2 (ADIPOR2) gene is associated with coronary artery disease and increased ADIPOR2 expression in peripheral monocytes,” Cardiovascular Diabetology, vol. 9, article 10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Frühbeck, J. Gómez-Ambrosi, F. J. Muruzábal, and M. A. Burrell, “The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation,” American Journal of Physiology, vol. 280, no. 6, pp. E827–E847, 2001. View at Google Scholar · View at Scopus
  44. M. Matsuda, I. Shimomura, M. Sata et al., “Role of adiponectin in preventing vascular stenosis,” Journal of Biological Chemistry, vol. 277, no. 40, pp. 37487–37491, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Pinto, D. Di Raimondo, A. Tuttolomondo, P. Fernandez, V. Arna, and G. Licata, “Twenty-four hour ambulatory blood pressure monitoring to evaluate effects on blood pressure of physical activity in hypertensive patients,” Clinical Journal of Sport Medicine, vol. 16, no. 3, pp. 238–243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Zietz, C. Buechler, K. Kobouch, M. Neumeier, J. Schölmerich, and A. Scäffler, “Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 9, pp. 532–536, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. R. P. F. Dullaart, R. de Vries, A. van Tol, and W. J. Sluiter, “Lower plasma adiponectin is a marker of increased intimamedia thickness associated with type 2 diabetes mellitus and with male gender,” European Journal of Endocrinology, vol. 156, no. 3, pp. 387–394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Nyström, A. Nygren, and Å. Sjöholm, “Increased levels of tumour necrosis factor-α (TNF-α) in patients with type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction,” Clinical Science, vol. 110, no. 6, pp. 673–681, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. H. A. Tuttle, G. Davis-Gorman, S. Goldman, J. G. Copeland, and P. F. McDonagh, “Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease,” Journal of Diabetes and its Complications, vol. 18, no. 6, pp. 343–351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. D. P. Misra, S. Das, and P. K. Sahu, “Prevalence of inflammatory markers (high-sensitivity C-reactive protein, nuclear factor-κB, and adiponectin) in Indian patients with type 2 diabetes mellitus with and without macrovascular complications,” Metabolic Syndrome and Related Disorders, vol. 10, no. 3, pp. 209–213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Davì, A. Tuttolomondo, F. Santilli et al., “CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke.,” Journal of atherosclerosis and thrombosis, vol. 16, no. 6, pp. 707–713, 2009. View at Google Scholar · View at Scopus
  52. A. Tuttolomondo, D. di Raimondo, R. Pecoraro, V. Arnao, A. Pinto, and G. Licata, “Inflammation in ischemic stroke subtypes,” Current Pharmaceutical Design, vol. 18, no. 28, pp. 4289–4310, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Licata, A. Tuttolomondo, S. Corrao et al., “Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state,” International Journal of Immunopathology and Pharmacology, vol. 19, no. 3, pp. 639–646, 2006. View at Google Scholar · View at Scopus
  54. A. Albanese, A. Tuttolomondo, C. Anile et al., “Spontaneous chronic subdural hematomas in young adults with a deficiency in coagulation factor XIII. Report of three cases,” Journal of Neurosurgery, vol. 102, no. 6, pp. 1130–1132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Tuttolomondo, D. Di Raimondo, G. I. Forte et al., “Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype,” Cytokine, vol. 58, no. 3, pp. 398–405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Tuttolomondo, D. di Raimondo, R. di Sciacca et al., “Arterial stiffness and ischemic stroke in subjects with and without metabolic syndrome,” Atherosclerosis, vol. 225, no. 1, pp. 216–219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Tuttolomondo, D. Di Raimondo, R. Pecoraro et al., “Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke,” Atherosclerosis, vol. 213, no. 1, pp. 311–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Pinto, A. Tuttolomondo, A. Casuccio et al., “Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF),” Clinical Science (Lond), vol. 116, no. 10, pp. 781–789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Tuttolomondo, D. Di Raimondo, R. Di Sciacca et al., “Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables,” Atherosclerosis, vol. 208, no. 1, pp. 290–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Strano, D. Hoppensteadt, J. M. Walenga et al., “Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease,” Seminars in Thrombosis and Hemostasis, vol. 22, supplement 1, pp. 35–40, 1996. View at Google Scholar
  61. G. Crepaldi, R. Fellin, A. Calabrò et al., “Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use,” Atherosclerosis, vol. 81, no. 3, pp. 233–243, 1990. View at Publisher · View at Google Scholar · View at Scopus